Invex Therapeutics Ltd (ASX: IXC) - Share Price
- Current share price for IXC : $0.130
Invex Therapeutics Ltd (IXC), an ASX-listed company, is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure. Invex has trademarked its repurposed Exenatide as Presendin.
IXC General Information +
| ASX Code | IXC |
| Website | http://www.invextherapeutics.com |
| Industry/Sector | Pharmaceuticals |
| Market Cap ($M) | 9 |
| IXC Share Price | $0.130 |
| Day High | $0.130 |
| Day Low | $0.130 |
| Last Close | $0.130 |
| IXC Share Price Movement | - ( No change ) |
Prices as at 16:40, 16 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Invex Therapeutics Ltd (IXC) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Invex Therapeutics Ltd (IXC) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Invex Therapeutics Ltd (IXC) price-sensitive announcements
IXC - Quarterly Activities/Appendix 4C Cash Flow Report
Invex Therapeutics Ltd, an Australian biopharmaceutical company, focuses on the repurposin
Invex Therapeutics Ltd (IXC)
24 Apr 2026 | 12:13 PM
24 Apr 2026 | 12:13 PM
IXC - Appendix 4D and Half Year Report
The half-year report for Invex Therapeutics Ltd, ending 31 December 2025, outlines the com
Invex Therapeutics Ltd (IXC)
12 Feb 2026 | 1:34 PM
12 Feb 2026 | 1:34 PM
IXC - Quarterly Activities/Appendix 4C Cash Flow Report
Invex Therapeutics Ltd, a biopharmaceutical company developing Exenatide for neurological
Invex Therapeutics Ltd (IXC)
22 Jan 2026 | 4:16 PM
22 Jan 2026 | 4:16 PM
IXC - Reinstatement to Quotation
On 10 November 2025, the ASX announced that the suspension of trading for Invex Therapeuti
Invex Therapeutics Ltd (IXC)
10 Nov 2025 | 9:38 AM
10 Nov 2025 | 9:38 AM
Invex Therapeutics Ltd (IXC) Recent ASX Announcements
IXC Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$0.48 | -$0.60 | -71.10% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$1.64 | -$2.20 | -78.90% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$7.75 | -$10.30 | 96.00% | 0.00 | 0.00 | 0.00% | 0.0% |
IXC Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| Clarity Pharmaceuticals Ltd (CU6) | $835M | 0.3002 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Invex Therapeutics Ltd (IXC) | $10M | -0.7110 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Neuren Pharmaceuticals Limited (NEU) | $1,636M | -0.7857 | 0.0743 | 1.2000 | 55.6511 | 51.8000 | 23.5455 | 0.00% | 0.00% | 0.00% |
IXC Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 1.86 | 0.00 |
| Market | 0.30 | 13.20 | 1.18 | 0.68 |
| Sector | 0.40 | 27.30 | 2.51 | 2.19 |
IXC Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Simon Llewellyn Owen | Non-Executive Director | 10 Nov 2025 |
| Mr David Colin Wheeler | Non-Executive Director | 8 Nov 2023 |
| Professor Warren John Harding | Non-Executive Director | 10 Nov 2025 |
Invex Therapeutics Ltd (IXC) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 27 Mar 2024 | DUTHY, Thomas (Tom) | Transfer | Indirect Shares | 285,661 | $0.075 | $21,424.580 |
| 27 Mar 2024 | DUTHY, Thomas (Tom) | Transfer | Indirect Shares | 285,661 | $0.075 | $21,424.580 |
| 24 Aug 2023 | DUTHY, Thomas (Tom) | Buy | Indirect Shares | 178,738 | $0.180 | $32,172.840 |
See all changes in directors' interest & trades for Invex Therapeutics Ltd (IXC) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
IXC Management
| Name | Position |
|---|---|
| Timothy (Tim) Ryan Slate | Company Secretary |
IXC Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Invex Therapeutics Ltd (IXC). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 8,846,154 (11.77%) | Tattarang Pty Ltd |
| 7,990,000 (10.63%) | Mr Jason Peterson |
IXC Calendar of Events
| Date | Event |
|---|---|
| 11 February 2027 | Report (Interim) |
| 10 August 2026 | Report (Annual) |
| 10 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
